1-(1,3-二甲基吡咯烷-3-基)甲胺 | 912771-31-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 1-(1,3-二甲基吡咯烷-3-基)甲胺
• 英文名称: (1,3-dimethylpyrrolidin-3-yl)methanamine
• CAS: 912771-31-4
• 化学式: C₇H₁₆N₂
• 分子量: 128.217
• InChiKey: HBEGEQPEVWXGGD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• WGK Germany：
  3

反应信息

• 作为反应物：
  描述：

  1-(1,3-二甲基吡咯烷-3-基)甲胺 、 3-iodo-5,7-diphenylpyrazolo[1,5-a]pyrimidine-2-carboxylic acid 在 三乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 N-((1,3-dimethylpyrrolidin-3-yl)methyl)-3-iodo-5,7-diphenylpyrazolo[1,5-a]pyrimidine-2-carboxamide
  参考文献：
  名称：

  [EN] PYRAZOLOPYRIMIDINES AS MODULATORS OF SPERMINE OXIDASE
  [FR] PYRAZOLOPYRIMIDINES UTILISÉES EN TANT QUE MODULATEURS DE LA SPERMINE OXYDASE

  摘要：

  The present invention comprises compounds of Formula (I). Wherein: R1, R2, R3, R4and R5are defined in the specification, and methods of treating or ameliorating a syndrome, disorder or disease described herein by administration of a therapeutically effective amount of at least one compound of Formula (I).

  公开号：

  WO2023141866A1

文献信息

• [EN] HETEROCYCLOALKYL-CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS<br/>[FR] THIÉNOPYRIMIDINES CONTENANT UN GROUPE HÉTÉROCYCLOALKYLE POUR DES COMPOSITIONS PHARMACEUTIQUES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2011104337A1

  公开（公告）日：2011-09-01

  The present invention relates to novel pharmaceutical compositions comprising thienopyrimidine compounds. Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.

  本发明涉及包含噻吩并嘧啶化合物的新颖药物组合物。此外，本发明涉及利用本发明的噻吩并嘧啶化合物生产药物组合物，用于预防和/或治疗可通过抑制Mnk1和/或Mnk2（Mnk2a或Mnk2b）及其变体的激酶活性而影响的疾病。
• HETEROCYCLOALKYL-CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS
  申请人：LEHMANN-LINTZ Thorsten

  公开号：US20110212102A1

  公开（公告）日：2011-09-01

  The present invention relates to novel pharmaceutical compositions comprising thienopyrimidine compounds. Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.

  本发明涉及包含噻吡啶并嘧啶化合物的新颖药物组合物。此外，本发明涉及利用本发明的噻吡啶并嘧啶化合物生产药物组合物，用于预防和/或治疗可通过抑制Mnk1和/或Mnk2（Mnk2a或Mnk2b）及其变体的激酶活性而影响的疾病。
• FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF
  申请人：Tabomedex Biosciences, LLC

  公开号：US20170190713A1

  公开（公告）日：2017-07-06

  Provided herein are substituted fused quadracyclic compounds useful as inhibitors of MK2. The invention further provides pharmaceutical compositions of the compounds of the invention. The invention also provides medical uses of substituted fused quadracyclic compounds.

  本文提供了作为MK2抑制剂有用的替代融合四环化合物。本发明还提供了所述化合物的药物组合物。本发明还提供了替代融合四环化合物的医药用途。
• TRICYCLIC GYRASE INHIBITORS
  申请人：TRIUS THERAPEUTICS INC.

  公开号：US20150246934A1

  公开（公告）日：2015-09-03

  Disclosed herein are compounds having the structure of Formula I and pharmaceutically suitable salts, esters, and prodrugs thereof that are useful as antibacterially effective tricyclic gyrase inhibitors. In addition, species of tricyclic gyrase inhibitors compounds are also disclosed herein. Related pharmaceutical compositions, uses and methods of making the compounds are also contemplated.

  本文揭示了具有I式结构的化合物及其药物适宜的盐、酯和前药，它们可用作具有抗菌作用的三环酶抑制剂。此外，本文还揭示了三环酶抑制剂化合物的种类。还考虑了相关的制药组合物、用途和制备化合物的方法。
• Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
  申请人：Array BioPharma, Inc.

  公开号：US10172845B2

  公开（公告）日：2019-01-08

  Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

  本文提供的是式 I 的化合物： 或其药学上可接受的盐或溶液，其中 A、B、X1、X2、X3、X4、环 D、E、Ra、Rb、n 和 m 具有说明书中给出的含义，它们是 RET 激酶的抑制剂，可用于治疗和预防可用 RET 激酶抑制剂治疗的疾病，包括 RET 相关疾病和失调。